Prostate Cancer Clinical Trial

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Summary

This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.

View Full Description

Full Description

The primary objective of this pilot study is to assess the safety and tolerability of DRibble vaccine, cyclophosphamide, imiquimod, and Ceravix in castrate resistant prostate cancer.

This study will also assess:

the immune profile of tumor biopsy specimens if sites amenable to biopsy are present
humoral and cellular responses to cancer antigens after DRibble vaccination
the response to a reporter antigen vaccine (Ceravix) after DRibble vaccination

An exploratory objective is to characterize the microbiome before and after study drugs administration and correlate prostate cancer responses.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subjects have measurable or evaluable metastatic castrate resistant adenocarcinoma of the prostate with progression after chemotherapy, combined androgen blockade and/or peripheral androgen or androgen receptor suppression. Either histologic or serum marker diagnosis is acceptable.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Ability to give informed consent and comply with the protocol.
Prior therapy with investigational agents must have been completed at least 3 weeks prior to study enrollment.
Patients must have normal organ and marrow function as determined by routine blood tests

Exclusion Criteria:

Active autoimmune disease except vitiligo or hypothyroidism.
Active other malignancy.
Known HIV positive and/or Hepatitis B or C positive.
Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in protocol.

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

3

Study ID:

NCT02234921

Recruitment Status:

Completed

Sponsor:

UbiVac

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Providence Health & Services
Portland Oregon, 97213, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

3

Study ID:

NCT02234921

Recruitment Status:

Completed

Sponsor:


UbiVac

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider